6533b82efe1ef96bd1293ad4
RESEARCH PRODUCT
530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)
S.r. ChandanaMatthew D. GalskyAndrés CervantesLisa G. HorvathMelissa Lynne JohnsonEmiliano CalvoHaeseong ParkLinda MileshkinRuth PlummerJ. EvansK. QuR.j. PelhamSiquing FuM. BarveV. MorenoA. StradellaSwati GoelL. Fariñas-madridAmy PrawiraTobias Arkenausubject
Oncologymedicine.medical_specialtyTemozolomidebusiness.industryLow doseLocally advancedHematologyPARP1OncologyInternal medicinemedicineBiomarker (medicine)businessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2020-09-01 | Annals of Oncology |